TP53 mutations were detected in 63% of total tumor samples; this percentage was lower in HPV-positive patients (31%) and higher in HPV-negative patients with oropharyngeal (77%) and hypopharyngeal (77%) cancer. The gene discussed is TP53; the disease is neoplasm.